BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Capecitabine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Capecitabine\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02008656-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT02008656)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Trial Evaluating 3-year Disease
  Free Survival in Patients With Locally Advanced Rectal Cancer Treated Wit
 h Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Me
 sorectal Excision or Non-operative Management\nEstimated primary completio
 n: November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cap
 ecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02008656
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04768426-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT04768426)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Serial Circulating Tumor DNA (c
 tDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Bre
 ast Cancer\nEstimated primary completion: November 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04768426
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118333-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06118333)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Study Comparing BL-B01D1 With
  Physician's Choice of Chemotherapy in Patients With Recurrent or Metastat
 ic Nasopharyngeal Carcinoma(PANKU-NPC01)\nEstimated primary completion: No
 vember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecita
 bine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06118333
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06648785-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06648785)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Modified Capecitabine and Oxali
 platin (mCAPOX) for Patients With GI Malignancies\nEstimated primary compl
 etion: November 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06648785
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750951-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07750951)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Single-arm\, Phase II Clinical 
 Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-3
 10 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Can
 cer\nEstimated primary completion: November 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07750951
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06885385-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261127
DTEND;VALUE=DATE:20261128
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06885385)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: A Phase 2 S
 tudy Evaluating the Safety and Efficacy of JS207 With or Without JS015 in 
 Combination With Chemotherapy in Patients With Colorectal Cancer\nEstimate
 d primary completion: 27 November 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06885385
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165772-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT04165772)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Study of Induction PD-1 Blockad
 e in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
 \nEstimated primary completion: 30 November 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04165772
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05093907-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT05093907)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: A Study t
 o Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine
  in Patients with Metastatic Colorectal Cancer\nEstimated primary completi
 on: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05093907
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06070740-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06070740)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: First- Line Treatment With Durv
 alumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine
  Carcinoma\nEstimated primary completion: 30 November 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06070740
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05700656-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT05700656)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: Galuniser
 tib Combined With Capecitabine in Advanced CRC With PM\nEstimated primary 
 completion: December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05700656
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800275-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05800275)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Capecitabine\, Tucatinib\, and Intrathecal Trastuzumab for Breast Ca
 ncer Patients With Leptomeningeal Disease\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecit
 abine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05800275
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065371-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 1 readout est. (NCT06065371)
DESCRIPTION:Capecitabine\, phase 1.\nStudy: Sacituzumab Govitecan in Combin
 ation With Capecitabine for Advanced Gastrointestinal Cancers After Progre
 ssion on Standard Therapy\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06065371
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06202261-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06202261)
DESCRIPTION:Capecitabine\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study of TQB2930 for Injection Monotherapy or Combination Therap
 y in Patients With Recurrent/Metastatic Breast Cancer\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06202261
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942767-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06942767)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Combination of QLS31905\, QL210
 7 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable
  Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ)
  Adenocarcinoma\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06942767
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06647680-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06647680)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Neoadjuvant Chemotherapy and PD
 -1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）\nEstimated
  primary completion: 1 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06647680
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06787183-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06787183)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: SCRT(Short Course Radiotherapy)
  Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases\nEstim
 ated primary completion: 1 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06787183
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06115733-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Capecitabine: Phase na readout est. (NCT06115733)
DESCRIPTION:Capecitabine\, phase na\, Colorectal Cancer.\nStudy: Study of F
 uquinitinib Combined With Capecitabine First-line Maintenance in the Treat
 ment of Metastatic Colorectal Cancer\nEstimated primary completion: 15 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitab
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06115733
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05171660-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Capecitabine: Phase 3 readout est. (NCT05171660)
DESCRIPTION:Capecitabine\, phase 3\, Colorectal Cancer.\nStudy: Combination
  With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant M
 etastatic Colorectal Cancer\nEstimated primary completion: 30 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05171660
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05731726-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05731726)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Serplulimab Combined With CAPEO
 X + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer\
 nEstimated primary completion: 30 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05731726
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01941641-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT01941641)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Colon Neoadjuvant FOLFOXIRI Stu
 dy\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT01941641
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03161522-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT03161522)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Chemotherapy W
 ith or Without Radiation or Surgery in Treating Participants With Oligomet
 astatic Esophageal or Gastric Cancer\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitab
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03161522
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03756298-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT03756298)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Efficacy and Safety of Atezoliz
 umab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breas
 t Cancer\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03756298
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04894643-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase na readout est. (NCT04894643)
DESCRIPTION:Capecitabine\, phase na\, Pancreatic Cancer.\nStudy: Preoperati
 ve\, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resect
 able Pancreatic Cancer\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04894643
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05838391-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase na readout est. (NCT05838391)
DESCRIPTION:Capecitabine\, phase na.\nStudy: Adaptive Radiation in Anal Can
 cer\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05838391
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06016387-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06016387)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Tucatinib\, Trastuzumab and Cap
 ecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER
 2+\, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Lepto
 meningeal Disease: A Multi-centre Phase II\, Single Arm Feasibility Study\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06016387
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533384-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06533384)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: PARPi or Capecitabine Combined 
 With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC\nEstimated prim
 ary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06533384
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06555471-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06555471)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: A Single-arm\,
  Phase II Exploratory Study of Sintilimab in Combination With Chemoradioth
 erapy in Elderly Patients With Locally Advanced Gastric Cancer\nEstimated 
 primary completion: 31 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06555471
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717464-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06717464)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Toripalimab Combined With Capec
 itabine as Postoperative Adjuvant Therapy for Patients With Resectable Adv
 anced Extrahepatic Biliary Tract Cancer\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capeci
 tabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06717464
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07068763-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07068763)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Node-Sparing Short-Course Radia
 tion Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cance
 r\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07068763
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239466-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07239466)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A Pilot Study Evaluating β-hyd
 roxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Foll
 owed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients
  With Locally Advanced Rectal Cancer\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitab
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07239466
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243951-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07243951)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Phase II Clinical Study on the 
 Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in 
 Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Ch
 olangiocarcinoma\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07243951
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06328738-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Capecitabine: Phase 1 readout est. (NCT06328738)
DESCRIPTION:Capecitabine\, phase 1\, Colorectal Cancer.\nStudy: ELVN-002 Wi
 th Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors\, Colorectal and Bre
 ast Cancer\nEstimated primary completion: January 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06328738
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06741644-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06741644)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: A Phase I/II Study of CS2009 
 in Participants With Advanced Solid Tumors\nEstimated primary completion: 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecit
 abine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06741644
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679399-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07679399)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A Phase II Study of Adjuvant Du
 rvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus
  Capecitabine in Biliary Tract Cancer.\nEstimated primary completion: 1 Ja
 nuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitab
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07679399
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06759090-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06759090)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Metronomic 
 Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Adva
 nced Pancreatic Cancer\nEstimated primary completion: 15 January 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06759090
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764940-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06764940)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capeci
 tabine in HER2-negative Breast Cancer Patients With Brain Metastases\nEsti
 mated primary completion: 15 January 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06764940
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06459869-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Capecitabine: Phase 1 readout est. (NCT06459869)
DESCRIPTION:Capecitabine\, phase 1.\nStudy: NG-350A Plus Chemoradiotherapy 
 for Locally Advanced Rectal Cancer\nEstimated primary completion: 30 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064
 59869
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229846-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07229846)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: A Single-ar
 m\, Single-center\, Phase II Clinical Study of Aipalolitovorelizumab (QL17
 06) Combined With Bevacizumab and Standard Chemotherapy as First-line Trea
 tment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation\n
 Estimated primary completion: February 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07229846
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239727-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06239727)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Reduced-dose Radiotherapy for S
 tage III Nasopharyngeal Carcinoma Based on the Treatment Response\nEstimat
 ed primary completion: 20 February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06239727
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06208410-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06208410)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: A Clinical Study of JS105 in 
 Combination With Other Anti-tumor Therapies in Patients With Solid Tumors\
 nEstimated primary completion: 26 February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06208410
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05062317-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05062317)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: ctDNA-Directed Post-Hepatectomy
  Chemotherapy for Patients With Resectable Colorectal Liver Metastases\nEs
 timated primary completion: 28 February 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05062317
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05929885-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05929885)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Metronomic 
 Capecitabine\, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Meta
 static Pancreatic Cancer Patients\nEstimated primary completion: 28 Februa
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059
 29885
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05172518-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Capecitabine: Phase 3 readout est. (NCT05172518)
DESCRIPTION:Capecitabine\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-
 negative Locally Advanced or Metastatic Breast Cancer\nEstimated primary c
 ompletion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05172518
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04595565-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Capecitabine: Phase 3 readout est. (NCT04595565)
DESCRIPTION:Capecitabine\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer\nEstima
 ted primary completion: 30 March 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04595565
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05040360-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05040360)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Testing the Use of Chemotherapy
  After Surgery for High-Risk Pancreatic Neuroendocrine Tumors\nEstimated p
 rimary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05040360
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104604-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07104604)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Study on the Efficacy and Safet
 y of Neoadjuvant Radiotherapy Combined With Tislelizumab\, Liposomal Irino
 tecan\, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal 
 Adenocarcinoma With Low Rectal Involvement\nEstimated primary completion: 
 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capeci
 tabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07104604
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03523312-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Capecitabine: Phase 2 readout est. (NCT03523312)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Use of High
 -dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Sur
 gical Treatment in Patients With Locally Advanced Pancreatic Cancer\nEstim
 ated primary completion: April 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03523312
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06409390)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Sequential Therapies Modeled on Evolutionary Dynamics for Breast Can
 cer\nEstimated primary completion: April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06761417-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06761417)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A Prospective\, Single-arm Clin
 ical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment 
 of Relapsed and Refractory Solid Tumors in Children\, Adolescents and Youn
 g Adults\nEstimated primary completion: 1 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06761417
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06888674-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06888674)
DESCRIPTION:Capecitabine\, phase 1/2\, Pancreatic Cancer.\nStudy: Personali
 zed Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pan
 creatic Cancer.\nEstimated primary completion: 1 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06888674
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04808323-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270414
DTEND;VALUE=DATE:20270415
SUMMARY:Capecitabine: Phase 1 readout est. (NCT04808323)
DESCRIPTION:Capecitabine\, phase 1.\nStudy: MRI-Guided Adaptive Radiation T
 herapy for Organ Preservation in Rectal Cancer\nEstimated primary completi
 on: 14 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ca
 pecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04808323
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06247995-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270414
DTEND;VALUE=DATE:20270415
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06247995)
DESCRIPTION:Capecitabine\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Phase I/II\, Dose Finding and Optimization Study of [177Lu]Lu-Ne
 oB in Combination With Capecitabine in Patients With GRPR+\, ER+\, HER2- M
 etastatic Breast Cancer After Progression on Previous Endocrine Therapy in
  Combination With a CDK4/6 Inhibitor.\nEstimated primary completion: 14 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 247995
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05794750-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270424
DTEND;VALUE=DATE:20270425
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05794750)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Assess the Efficacy of Radiothe
 rapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CR
 C（AK104-IIT-13）\nEstimated primary completion: 24 April 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05794750
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07056777-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07056777)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: Evaluation of the Preliminary
  Efficacy and Safety of DR30206 in Combination With Standard Therapy in Pa
 tients With Gastrointestinal Cancer\nEstimated primary completion: 30 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0705
 6777
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281157-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07281157)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Liposomal Irinotecan\, Capecita
 bine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced 
 Rectal Cancer\nEstimated primary completion: 30 April 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07281157
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05228431-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05228431)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Modified Sandwich Therapeutic R
 egimen for Locally Advanced Rectal Cancer\nEstimated primary completion: 1
  May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5228431
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04379596-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Capecitabine: Phase 2 readout est. (NCT04379596)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Ph1b/2 Study o
 f the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressin
 g Gastric Cancer (DESTINY-Gastric03)\nEstimated primary completion: 4 May 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT043795
 96
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07462143-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT07462143)
DESCRIPTION:Capecitabine\, phase 2/3\, Colorectal Cancer.\nStudy: A Phase 
 Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unrese
 ctable or Metastatic Colorectal Cancer\nEstimated primary completion: 12 M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 62143
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07570914-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07570914)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Hepatic Art
 erial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine a
 s Adjuvant Therapy for Colorectal Cancer Liver Metastases\nEstimated prima
 ry completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07570914
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05876065-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Capecitabine: Phase na readout est. (NCT05876065)
DESCRIPTION:Capecitabine\, phase na\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for A
 dvanced Breast Cancer\nEstimated primary completion: June 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05876065
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653685-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07653685)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: A Clinica
 l Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Beva
 cizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Ad
 vanced or Metastatic Colorectal Cancer.\nEstimated primary completion: Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0765
 3685
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03907475-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Capecitabine: Phase 2 readout est. (NCT03907475)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Durvalumab in Combination With 
 Chemotherapy in Treating Patients With Advanced Solid Tumors\, DURVA+ Tria
 l\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03907475
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532006-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06532006)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: A Phase Ⅲ Cl
 inical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for
  the Treatment of Gastroesophageal Junction and Gastric Cancer\nEstimated 
 primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06532006
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04495296-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT04495296)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: A Trial to Evaluate Safety\, 
 Tolerability\, Pharmacokinetics and Preliminary Efficacy of TST001 in Adva
 nced or Metastatic Solid Tumors\nEstimated primary completion: 30 June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04495296
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05803382-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Capecitabine: Phase 1 readout est. (NCT05803382)
DESCRIPTION:Capecitabine\, phase 1\, Colorectal Cancer.\nStudy: Testing the
  Addition of an Anti-Cancer Drug\, ZEN003694\, to the Usual Chemotherapy T
 reatment (Capecitabine) for Metastatic or Unresectable Cancers\nEstimated 
 primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05803382
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942234-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06942234)
DESCRIPTION:Capecitabine\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Study of JSKN016 Combination Therapy in Inoperable Locally Advance
 d or Metastatic HER2-Negative Breast Cancer\nEstimated primary completion:
  30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capeci
 tabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06942234
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07692750-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07692750)
DESCRIPTION:Capecitabine\, phase 1/2\, Pancreatic Cancer.\nStudy: IBI343 Co
 mbined With Chemotherapy in Advanced Pancreatic Cancer\nEstimated primary 
 completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07692750
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07051785-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270706
DTEND;VALUE=DATE:20270707
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07051785)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Fruquintini
 b vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Sec
 ond-Line Therapy for Advanced Metastatic Colorectal Cancer\nEstimated prim
 ary completion: 6 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07051785
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158164-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270707
DTEND;VALUE=DATE:20270708
SUMMARY:Capecitabine: Phase 4 readout est. (NCT07158164)
DESCRIPTION:Capecitabine\, phase 4\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment\nEst
 imated primary completion: 7 July 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07158164
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04997837-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270721
DTEND;VALUE=DATE:20270722
SUMMARY:Capecitabine: Phase 3 readout est. (NCT04997837)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Study of Adjuv
 ant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in 
 Resected pN3 Gastric (G) or GEJ Adenocarcinoma\nEstimated primary completi
 on: 21 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cap
 ecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04997837
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06602167-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Capecitabine: Phase na readout est. (NCT06602167)
DESCRIPTION:Capecitabine\, phase na\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Electroacupuncture Combined With Self-administered Acupressure for 
 the Prevention of Capecitabine-Associated Hand-Foot Syndrome\nEstimated pr
 imary completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06602167
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02945566-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT02945566)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: Can we Save the Rectum by Wat
 chful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus To
 tal Mesorectal Excision for Early REctal Cancer?\nEstimated primary comple
 tion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ca
 pecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT02945566
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04501523-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Capecitabine: Phase 2 readout est. (NCT04501523)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A Prospective\, Phase II Trial 
 Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC\nEs
 timated primary completion: August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04501523
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185672-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270807
DTEND;VALUE=DATE:20270808
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07185672)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: PRRT Versus PRRT Plus Chemother
 apy in GEP NET (PReCedeNT Trial)\nEstimated primary completion: 7 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0718567
 2
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469306-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07469306)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Short-Course RT Plus CAPOX and 
 Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rec
 tal Cancer\nEstimated primary completion: 10 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07469306
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06790212-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06790212)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Neoadjuvant CAPOX Plus Ivonesci
 mab Versus CAPOX for Locally Advanced Colon Cancer\nEstimated primary comp
 letion: 30 August 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06790212
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05693766-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05693766)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort\nEstimat
 ed primary completion: 31 August 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05693766
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150949-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07150949)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Long-course Chemoradiotherapy o
 r Short-course Radiotherapy Combined With CAPOX\, PD-1antibody\, and COX-2
  Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)\nEstimated prim
 ary completion: 31 August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07150949
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05484375-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05484375)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Capecitabine Plus Toripalimab M
 aintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line
  Treatment\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05484375
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06991465-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06991465)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Organ Preservation in Rectal Ad
 enoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)\nEstimated primary compl
 etion: September 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06991465
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215936-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07215936)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Dose-dense 
 Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Compa
 rison With Standered Regimen\nEstimated primary completion: September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07215936
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05851924-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05851924)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A Study of NALIRIFOX in Combina
 tion With Radiation Therapy in People With Pancreatic Ductal Adenocarcinom
 a (PDAC)\nEstimated primary completion: 1 September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05851924
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05976568-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT05976568)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: A Study of QL1706 in Combinat
 ion With Bevacizumab and/or Chemotherapy as First-line Treatment in Patien
 ts With Advanced Hepatocellular Carcinoma\nEstimated primary completion: 1
  September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cape
 citabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05976568
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06204094-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06204094)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Node-sparing Radiotherapy Combi
 ned With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rec
 tal Cancer\nEstimated primary completion: 1 September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06204094
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06560528-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06560528)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Disitamab Vedo
 tin Combined With Tislelizumab and Capecitabine in the Perioperative Treat
 ment of Locally Advanced Gastric Cancer With HER2 Overexpression\nEstimate
 d primary completion: 1 September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06560528
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06578052-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Capecitabine: Phase na readout est. (NCT06578052)
DESCRIPTION:Capecitabine\, phase na\, Pancreatic Cancer.\nStudy: Irinotecan
  Liposome in Combination With Capecitabine\nEstimated primary completion: 
 1 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cap
 ecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06578052
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788171-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06788171)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: PULSAR Comb
 ined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM\nEstimated primary c
 ompletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06788171
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05265208-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270904
DTEND;VALUE=DATE:20270905
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05265208)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Selective Internal Radiation Th
 erapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer\nEstimate
 d primary completion: 4 September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05265208
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01061515-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270927
DTEND;VALUE=DATE:20270928
SUMMARY:Capecitabine: Phase 1 readout est. (NCT01061515)
DESCRIPTION:Capecitabine\, phase 1\, Colorectal Cancer.\nStudy: Biweekly In
 traperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for P
 atients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Canc
 er\nEstimated primary completion: 27 September 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT01061515
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955940-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Capecitabine: Phase 2 readout est. (NCT02955940)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: An Open-Label Study to Enable Continued Treatment Access for Subject
 s Previously Enrolled in Studies of Ruxolitinib\nEstimated primary complet
 ion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02955940
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140393-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07140393)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: A Study of HRS-4508 in Combin
 ation With Other Anti-tumor Therapy for Solid Tumor\nEstimated primary com
 pletion: October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07140393
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296666-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07296666)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Adjuvant Chemotherapy for BTC B
 ased on 3D-PTA\nEstimated primary completion: October 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07296666
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05247905-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05247905)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Comparing Capecitabine and Temo
 zolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advan
 ced Pancreatic Neuroendocrine Tumors\, the ComPareNET Trial\nEstimated pri
 mary completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05247905
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Study of Da
 to-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patien
 ts With Advanced Solid Tumours (TROPION-PanTumor03)\nEstimated primary com
 pletion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05489211
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898865-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07898865)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: NeoCSR-Omics Trial: CAPOX + Ser
 plulimab Before vs. After Short-course RT in LARC\nEstimated primary compl
 etion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07898865
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06544655-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271014
DTEND;VALUE=DATE:20271015
SUMMARY:Capecitabine: Phase 1 readout est. (NCT06544655)
DESCRIPTION:Capecitabine\, phase 1.\nStudy: A Study of BMS-986484 Alone and
  Combination Therapy in Participants With Advanced Solid Tumors\nEstimated
  primary completion: 14 October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06544655
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407465-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07407465)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Upfront Tra
 stuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HE
 R-2 Positive Metastatic Colorectal Cancer.\nEstimated primary completion: 
 20 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cape
 citabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07407465
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043400-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07043400)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Study to Investigate Tisleliz
 umab Administered as Subcutaneous Injection Versus Intravenous Infusion Pl
 us Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gas
 troesophageal Junction Adenocarcinoma\nEstimated primary completion: 30 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitab
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07043400
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04615013-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Capecitabine: Phase 1 readout est. (NCT04615013)
DESCRIPTION:Capecitabine\, phase 1.\nStudy: NBTXR3\, Chemotherapy\, and Rad
 iation Therapy for the Treatment of Esophageal Cancer\nEstimated primary c
 ompletion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04615013
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547385-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Capecitabine: Phase 1 readout est. (NCT06547385)
DESCRIPTION:Capecitabine\, phase 1\, Colorectal Cancer.\nStudy: Study of ON
 O-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer\nEstimated p
 rimary completion: 31 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06547385
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828756-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07828756)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Albumin-bou
 nd Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer\nEstimated pri
 mary completion: 31 October 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07828756
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847229-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07847229)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A Prospective\, Biomarker-Strat
 ified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Shor
 t-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus 
 Chemotherapy Alone in Locally Advanced Rectal Cancer\nEstimated primary co
 mpletion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07847229
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05494190-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Capecitabine: Phase na readout est. (NCT05494190)
DESCRIPTION:Capecitabine\, phase na.\nStudy: The Management of Metastatic N
 eck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma\nEstimated primar
 y completion: November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05494190
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06800391-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06800391)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Metronomic Neoadjuvant Capecita
 bine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients\nEstimat
 ed primary completion: November 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06800391
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780787-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06780787)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: FOLFOX\, Botensilimab\, and Bal
 stilimab for the Treatment of Localized Rectal Cancer Before Surgery\nEsti
 mated primary completion: 5 November 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06780787
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07069712-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271109
DTEND;VALUE=DATE:20271110
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07069712)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A Study of Novel Agents or Comb
 inations as Perioperative Treatment in Participants With Locally Advanced 
 Resectable Gastroesophageal Adenocarcinoma\nEstimated primary completion: 
 9 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cape
 citabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07069712
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07449780-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271117
DTEND;VALUE=DATE:20271118
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07449780)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Study of AK104 (SC) in Combin
 ation With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combi
 nation With XELOX in Participants With Unresectable Locally Advanced or Me
 tastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinom
 a\nEstimated primary completion: 17 November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07449780
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05702229-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05702229)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Novel Combinat
 ions in Participants With Locally Advanced Unresectable or Metastatic Gast
 ric or Gastroesophageal Junction Adenocarcinoma\nEstimated primary complet
 ion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05702229
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123338-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06123338)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: A Study of Pem
 brolizumab With Trastuzumab and Chemotherapy in People With Esophagogastri
 c Cancer\nEstimated primary completion: 30 November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06123338
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671822-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05671822)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Ph1b/2 Study o
 f the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expre
 ssion Gastric Cancer\nEstimated primary completion: December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05671822
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007559-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07007559)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: ASPEN-09-03: A Study of Evorpac
 ept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Po
 sitive Breast Cancer\nEstimated primary completion: December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07007559
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07561060-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07561060)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: Low Rectal Cancer Treated Wit
 h Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy\nEs
 timated primary completion: December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07561060
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680569-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07680569)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: Phase Ib/IIa Open-label Study
 \, to Evaluate Safety\, Tolerability\, and Antitumor Activity of HCB101 in
  Combination With Multiple Agents in Subjects With Advanced Gastric or Gas
 tro-esophageal (GEJ) Adenocarcinoma\nEstimated primary completion: Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0768
 0569
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05869227-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Capecitabine: Phase 3 readout est. (NCT05869227)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Maintenance Therapy With Toripa
 limab Combined With Capecitabine/Placebo for Recurrent and Metastatic Naso
 pharyngeal Carcinoma\nEstimated primary completion: 20 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05869227
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05472948-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05472948)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Surufatinib and Sintilimab in C
 ombination With Capecitabine for Metastatic Adenocarcinoma of Small Intest
 ine or Appendix Carcinoma\nEstimated primary completion: 30 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05472948
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785741-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT05785741)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: A Study of DB-1310 in Advance
 d/Metastatic Solid Tumors\nEstimated primary completion: 30 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05785741
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503756-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07503756)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: JS212 Combi
 nation Therapies in Metastatic Colorectal Cancer\nEstimated primary comple
 tion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07503756
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566380-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT04566380)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: ONO-4538 Phase II Rollover Stud
 y (ONO-4538-98)\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04566380
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05502393-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 1 readout est. (NCT05502393)
DESCRIPTION:Capecitabine\, phase 1.\nStudy: A Clinical Study to Evaluate th
 e Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05502393
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07331428-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07331428)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: MRG003 Induction and Capecitabi
 ne Maintenance With PD-1 in Locally Recurrent NPC\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07331428
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477743-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 1 readout est. (NCT07477743)
DESCRIPTION:Capecitabine\, phase 1.\nStudy: A Phase Ib Clinical Study on th
 e Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07477743
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490262-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT07490262)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: A Study to Evaluate the Effic
 acy and Safety of IBI310 and Sintilimab Combination Therapy in Patients Wi
 th Hepatocellular Carcinoma as First-line Treatment.\nEstimated primary co
 mpletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07490262
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494448-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07494448)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: Phase Ib/II Study of Zanidata
 mab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cance
 r\nEstimated primary completion: 31 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07494448
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562659-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07562659)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Randomized 
 Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy 
 in Stage I/Low-Risk Stage II Colorectal Cancer\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07562659
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07690787-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07690787)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: JS207 a Bispecific Antibody Aga
 inst PD1-VEGF in Nasopharyngeal Carcinoma\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cape
 citabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07690787
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691632-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07691632)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Serplulimab
  Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal 
 Cancer\nEstimated primary completion: 31 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07691632
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738042-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase na readout est. (NCT07738042)
DESCRIPTION:Capecitabine\, phase na.\nStudy: To Explore a Single-arm Phase 
 II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvan
 t Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer U
 nder MSS/pMMR\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07738042
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07837362-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07837362)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: SCRT Combined With CAPOX and PD
 -1/CTLA4 Antibody for Early-stage Low Rectal Cancer\nEstimated primary com
 pletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07837362
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933679-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07933679)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: SCRT Combined With CAPOX and PD
 -1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Can
 cer (TORCH-E3)\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07933679
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05912075-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Capecitabine: Phase 1 readout est. (NCT05912075)
DESCRIPTION:Capecitabine\, phase 1.\nStudy: Preoperative Radiotherapy And A
 STX660 in Rectum Cancer\nEstimated primary completion: 1 January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05912075
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06719479-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT06719479)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: A Clinical Trial to Evaluate 
 Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It
  is Currently Phase II.).\nEstimated primary completion: 1 January 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06719479
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771622-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06771622)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: Safety and Efficacy of HCB101
  in Combination With Multiple Agents in Patients With Advanced Solid Tumor
 s\nEstimated primary completion: 1 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06771622
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113275-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07113275)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Clinical Trial Comparing Long
 -Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combine
 d With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followe
 d by TNT in Locally Advanced Rectal Cancer\nEstimated primary completion: 
 1 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capec
 itabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07113275
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07254962-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07254962)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: CApecitabine Prior to TUmor Res
 ection in Ent Oncology (CAPTURE)\nEstimated primary completion: 1 January 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072549
 62
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07774754-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07774754)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Radiotherapy Combined With Cape
 ox Chemotherapy\, Sintilimab and Suvemcitug in Locally Advanced pMMR Recta
 l Cancer:a Prospective Clinical Trial\nEstimated primary completion: 1 Jan
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7774754
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366840-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280116
DTEND;VALUE=DATE:20280117
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT07366840)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: RC48 Combined With Chemothera
 py in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC F
 ailure\nEstimated primary completion: 16 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07366840
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07691333-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07691333)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Kumorixilib Plus Capecitabine a
 nd Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast
  Cancer\nEstimated primary completion: 30 January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07691333
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024615-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Capecitabine: Phase 1 readout est. (NCT07024615)
DESCRIPTION:Capecitabine\, phase 1.\nStudy: A Study of ASP2138 Given Before
  Surgery\, Then Chemotherapy After Surgery\, in People With Pancreatic Duc
 tal Cancer\nEstimated primary completion: 31 January 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07024615
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07652242-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Capecitabine: Phase 1 readout est. (NCT07652242)
DESCRIPTION:Capecitabine\, phase 1.\nStudy: Phase 1 Study of a Self-amplify
 ing RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer\nEst
 imated primary completion: February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07652242
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06888843-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06888843)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Study to Ev
 aluate the Use of Capecitabine in Monotherapy and in Combination With Oxal
 iplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced 
 Colorectal Cancer.\nEstimated primary completion: 1 February 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06888843
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684456-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07684456)
DESCRIPTION:Capecitabine\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Efficacy and Safety of Utidelone Capsule and Utidelone Injection in 
 Patients With HER-2 Negative Advanced Breast Cancer\nEstimated primary com
 pletion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07684456
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847710-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07847710)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Perioperative Retlirafusp Alfa(
 Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Ba
 sed Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepat
 ic Cholangiocarcinoma: A Multicenter\, Single-Arm\, Exploratory Phase II T
 rial\nEstimated primary completion: 1 March 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07847710
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04248452-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Capecitabine: Phase 3 readout est. (NCT04248452)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Testing the Ad
 dition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients 
 With Esophageal and Gastric Cancer That Has Spread to a Limited Number of 
 Other Places in the Body\nEstimated primary completion: 31 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04248452
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05034887-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05034887)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Phase 2 Study of Trastuzumab De
 ruxtecan in the Neoadjuvant Treatment\, or Trastuzumab Deruxtecan Plus Cap
 ecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative 
 Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesoph
 ageal Junction Adenocarcinoma\nEstimated primary completion: 31 March 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05034887
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474103-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Capecitabine: Phase na readout est. (NCT07474103)
DESCRIPTION:Capecitabine\, phase na.\nStudy: SCRT-NALIRIXELOX+Sintilimab as
  TNT for High-Risk LARC\nEstimated primary completion: 31 March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07474103
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503639-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07503639)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Umbrella Tr
 ial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer\nEstimat
 ed primary completion: April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07503639
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551778-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07551778)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: Allogenei
 c NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced
  Solid Tumors\nEstimated primary completion: April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07551778
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07515625-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07515625)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Efficacy of Si
 ntilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable
  AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma\nEstimated 
 primary completion: 1 April 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07515625
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435429-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06435429)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Study Comparing the Efficacy 
 and Safety of Zanidatamab to Trastuzumab\, Each in Combination With Physic
 ian's Choice Chemotherapy\, for the Treatment of Participants With Metasta
 tic HER2-positive Breast Cancer\nEstimated primary completion: 28 April 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06435429
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06839105-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Capecitabine: Phase 1 readout est. (NCT06839105)
DESCRIPTION:Capecitabine\, phase 1\, Colorectal Cancer.\nStudy: A Clinical 
 Study to Evaluate the Safety and Tolerability of AWT020 in Patients With A
 dvanced Malignancies\nEstimated primary completion: 30 April 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06839105
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07456852-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07456852)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: Vasodilator Therapy With Isos
 orbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Ga
 strointestinal Cancer Receiving Fluoropyrimidine Therapy\nEstimated primar
 y completion: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07456852
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824934-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Capecitabine: Phase 1 readout est. (NCT07824934)
DESCRIPTION:Capecitabine\, phase 1.\nStudy: HEC-921 Injection as Monotherap
 y and in Combination With Antineoplastic Therapies in Patients With Advanc
 ed Malignant Solid Tumors\nEstimated primary completion: May 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07824934
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621484-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07621484)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: HIPEC Priming 
 Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer\
 nEstimated primary completion: 9 May 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07621484
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944496-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06944496)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Study of Disitamab Vedotin Co
 mbined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined Wit
 h Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction A
 denocarcinoma\nEstimated primary completion: 15 May 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06944496
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06949111-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06949111)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Radiotherapy + Systemic Therapy
  as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）\nEsti
 mated primary completion: 30 May 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06949111
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07390383-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07390383)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A Phase II Clinical Trial of LB
 L-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
 \nEstimated primary completion: 30 May 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07390383
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05365581-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Capecitabine: Phase 1 readout est. (NCT05365581)
DESCRIPTION:Capecitabine\, phase 1\, Pancreatic Cancer.\nStudy: A Study of 
 ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults Wi
 th Stomach Cancer\, Gastroesophageal Junction Cancer\, or Pancreatic Cance
 r\nEstimated primary completion: 31 May 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05365581
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177794-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07177794)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Consolidation of Toripalimab an
 d Capecitabine After Chemoradiotherapy in ESCC\nEstimated primary completi
 on: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cape
 citabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07177794
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03213002-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT03213002)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: Oral Capecitabine and Temozol
 omide (CAPTEM) for Newly Diagnosed GBM\nEstimated primary completion: June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03213
 002
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06105684-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06105684)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase II Single Arm Trial of Low Dose Capecitabine in Patients With 
 Advanced Breast Cancer\nEstimated primary completion: June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06105684
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685704-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07685704)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Zanidatamab Co
 mbined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positi
 ve (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenoc
 arcinoma: a Phase II Open-Label Study\nEstimated primary completion: June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076857
 04
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06598046-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06598046)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A Single-arm\, Prospective Phas
 e Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatm
 ent of Active Brain Metastasis of TNBC\nEstimated primary completion: 1 Ju
 ne 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 98046
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992882-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280608
DTEND;VALUE=DATE:20280609
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06992882)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Randomized\, Open-label\, Mul
 ti-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Comb
 ined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the A
 djuvant Treatment of HER2-positive\, Lymph Node-negative Early Breast Canc
 er Patients(ORCHID-PLUS)\nEstimated primary completion: 8 June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06992882
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01935778-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Capecitabine: Phase 3 readout est. (NCT01935778)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Compare Adjuva
 nt Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/O
 xaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): 
 TRIUMPH\nEstimated primary completion: 30 June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT01935778
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998771-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06998771)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: JSKN003 Combin
 ed Treatment of HER2-positive Gastric Cancer\nEstimated primary completion
 : 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capec
 itabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06998771
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609667-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07609667)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: SKB315 in Combination Therapy i
 n Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma\nEstimated p
 rimary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07609667
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841873-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07841873)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Zanidatamab Combined With Lipos
 omal Irinotecan and Capecitabine for Second-line Treatment of HER2-positiv
 e Unresectable Biliary Tract Tumors\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07841
 873
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04339036-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Capecitabine: Phase 2 readout est. (NCT04339036)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: CapTemY90 for Grade 2/3 NET Liv
 er Metastases\nEstimated primary completion: 1 July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04339036
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381777-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07381777)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: XELOX Plus DoSTARlimab Versus X
 ELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMM
 R/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients\nEstimated
  primary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07381777
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655661-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07655661)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Mannatide Comb
 ined With CAPOX and Tislelizumab for Advanced Gastric Cancer.\nEstimated p
 rimary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07655661
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243938-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07243938)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Phase II Ba
 sket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNIO
 N-HER2-BASKET)\nEstimated primary completion: 30 July 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07243938
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07019337-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07019337)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Oral Metronomic Capecitabine Co
 mbined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cance
 r\nEstimated primary completion: 31 July 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07019337
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112053-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07112053)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemoth
 erapy for the Treatment of Metastatic Hormone Receptor Positive\, HER2 Neg
 ative Breast Cancer\nEstimated primary completion: 31 July 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07112053
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05973864-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05973864)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Capecitabine Plus Pembrolizumab
  in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy 
 and Surgery\nEstimated primary completion: August 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05973864
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681297-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07681297)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: Tislelizumab in Combination W
 ith Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation 
 in Immunotherapy-Resistant and Central Nervous System Disease\nEstimated p
 rimary completion: August 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07681297
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134101-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07134101)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Neoadjuvant
  Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)\nEstimated p
 rimary completion: 31 August 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07134101
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716449-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07716449)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: QLS31905 in Combination With CA
 POX Versus Sintilimab in Combination With CAPOX as First-line Treatment in
  Patients With GC/GEJ\nEstimated primary completion: September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07716449
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04803539-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT04803539)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: A Prospective\, Phase II Tria
 l Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chem
 otherapy in TNBC\nEstimated primary completion: 1 September 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04803539
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07833241-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07833241)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Surufatinib
  in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemoth
 erapy for Neoadjuvant Therapy of HRPC or BRPC\nEstimated primary completio
 n: 1 September 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07833241
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07800000-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280919
DTEND;VALUE=DATE:20280920
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07800000)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Becotatug Vedotin Plus Pucotenl
 imab and Capecitabine Followed by Concurrent Chemoradiotherapy-Immunothera
 py for Locally Advanced Squamous Cell Carcinoma of the Anal Canal\nEstimat
 ed primary completion: 19 September 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07800000
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913516-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Capecitabine: Phase na readout est. (NCT07913516)
DESCRIPTION:Capecitabine\, phase na\, Colorectal Cancer.\nStudy: Feasibilit
 y Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse React
 ions in Advanced Colorectal Cancer\nEstimated primary completion: 30 Septe
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7913516
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06093061-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06093061)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Tislelizumab and Metronomic Cap
 ecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharynge
 al Carcinoma\nEstimated primary completion: October 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06093061
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859410-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Capecitabine: Phase na readout est. (NCT07859410)
DESCRIPTION:Capecitabine\, phase na.\nStudy: Sintilimab Combined With Chemo
 radiotherapy as Neoadjuvant Therapy for Locally Advanced Gastroesophageal 
 Junction Cancer\nEstimated primary completion: 1 October 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07859410
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07893392-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281008
DTEND;VALUE=DATE:20281009
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07893392)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Phase II Study of Primary Tumor
  Resection and Selective Lymph Node Dissection Followed by RT for BTC With
  Lymph Node Metastases\nEstimated primary completion: 8 October 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07893392
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630130-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06630130)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Perioperative 
 Therapies in Locally Advanced Unresectable Gastric Cancer\nEstimated prima
 ry completion: 30 October 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06630130
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112379-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281120
DTEND;VALUE=DATE:20281121
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06112379)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Phase III Randomised Study to
  Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Tr
 iple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer\nEstimat
 ed primary completion: 20 November 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06112379
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03351296-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT03351296)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Two Chemoth
 erapy Regimens Plus or Minus Bevacizumab\nEstimated primary completion: De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecita
 bine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03351296
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05288777-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT05288777)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: Adjuvant Chemoradiation and B
 iomarkers of Response in High-risk Breast Cancer\nEstimated primary comple
 tion: December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05288777
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07737600-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07737600)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: A Study o
 f MRG007 Combination Therapy for Advanced Colorectal Cancer\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07737600
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874425-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07874425)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Retlirafusp Al
 fa Combined With Zeprumetostat\, Apatinib\, and Chemotherapy as First-Line
  Treatment for Metastatic GC/GEJC\nEstimated primary completion: December 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078744
 25
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07331155-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281226
DTEND;VALUE=DATE:20281227
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07331155)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A Phase II Clinical Study of LB
 L-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 
 03(ESCC)]\nEstimated primary completion: 26 December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07331155
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384234-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07384234)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: SHR-1701 Combined With Chemothe
 rapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritone
 al Metastasis\nEstimated primary completion: 30 December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07384234
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709767-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07709767)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Conversion Therapy With Retlira
 fusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenoc
 arcinoma\nEstimated primary completion: 30 December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07709767
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04523818-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 1 readout est. (NCT04523818)
DESCRIPTION:Capecitabine\, phase 1\, Gastric Cancer.\nStudy: Short-Course C
 hemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable 
 Gastric Adenocarcinoma\nEstimated primary completion: 31 December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04523818
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06751394-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06751394)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Preoperative Chemoradiotherapy 
 and Toripalimab in Locally Recurrent Rectal Cancer\nEstimated primary comp
 letion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06751394
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06787339-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06787339)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Capecitabine in Low Risk Triple
  Negative Breast Cancer\nEstimated primary completion: 31 December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06787339
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963502-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 1 readout est. (NCT06963502)
DESCRIPTION:Capecitabine\, phase 1\, Colorectal Cancer.\nStudy: A Phase Ib 
 Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients W
 ith Advanced Solid Tumors\nEstimated primary completion: 31 December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06963502
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483060-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 4 readout est. (NCT07483060)
DESCRIPTION:Capecitabine\, phase 4.\nStudy: Next Generation STAR-TREC (NG-S
 T) - Organ Preservation in Early Rectal Cancer\nEstimated primary completi
 on: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07483060
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622797-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07622797)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Exploratory Clinical Study of C
 amrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserv
 ing Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carc
 inoma\nEstimated primary completion: 31 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07622797
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677293-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07677293)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Retlirafusp Al
 fa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 A
 ntibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Can
 cer With Liver Metastases\nEstimated primary completion: 31 December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07677293
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622017-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07622017)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: KORTUC (KRC-01) Plus Radiothera
 py for Organ Preservation in Rectal Cancer\nEstimated primary completion: 
 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecit
 abine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07622017
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324357-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06324357)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: Beamion B
 CGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Co
 mbination With Other Treatments to Test Whether it Helps People With Diffe
 rent Types of HER2+ Cancer That Has Spread\nEstimated primary completion: 
 8 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capec
 itabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06324357
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07417241-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07417241)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: SHR-A1811 vs Pyrotinib/Capecita
 bine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized S
 tudy\nEstimated primary completion: 31 January 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07417241
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07584135-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07584135)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: JS107 in Combination With Torip
 alimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or 
 Gastroesophageal Junction Adenocarcinoma\nEstimated primary completion: 31
  January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capeci
 tabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07584135
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335497-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07335497)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: CR-001 in Adult Participants 
 With Locally Advanced or Metastatic Solid Tumors\nEstimated primary comple
 tion: February 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07335497
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395063-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07395063)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: A Clinical 
 Study on the Treatment of Metastatic Colorectal Cancer at the Second-line 
 or Beyond.\nEstimated primary completion: 1 February 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07395063
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797077-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290220
DTEND;VALUE=DATE:20290221
SUMMARY:Capecitabine: Phase 3 readout est. (NCT05797077)
DESCRIPTION:Capecitabine\, phase 3\, Colorectal Cancer.\nStudy: Postoperati
 on Maintenance Therapy for Resectable Liver Metastases of Colorectal Cance
 r Guided by ctDNA\nEstimated primary completion: 20 February 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05797077
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904845-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290227
DTEND;VALUE=DATE:20290228
SUMMARY:Capecitabine: Phase 1 readout est. (NCT07904845)
DESCRIPTION:Capecitabine\, phase 1.\nStudy: A Study of BON-C1393 in Adults 
 With Advanced Solid Tumors\nEstimated primary completion: 27 February 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07904845
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636824-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07636824)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Efficacy and Safety of Postoper
 ative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and
  Gallbladder Carcinoma: A Multicenter Prospective Phase II Study\nEstimate
 d primary completion: 28 February 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07636824
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07692152-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07692152)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Sintilimab Versus Mitomycin in 
 Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cel
 l Carcinoma\nEstimated primary completion: March 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07692152
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06313567-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290310
DTEND;VALUE=DATE:20290311
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06313567)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Metronomic Cap
 ecitabine in Stage III Gastric Cancer\nEstimated primary completion: 10 Ma
 rch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 313567
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007182-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07007182)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Conversion The
 rapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in
  Gastric Cancer\nEstimated primary completion: 1 April 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07007182
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509424-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290410
DTEND;VALUE=DATE:20290411
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07509424)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Neoadjuvant Short-course Radiot
 herapy Followed by a Combination of Disitamab Vedotin\, Sintilimab\, and C
 apecitabine in Locally Advanced HER2-expressing Rectal Cance\nEstimated pr
 imary completion: 10 April 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07509424
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764875-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290427
DTEND;VALUE=DATE:20290428
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06764875)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: A Phase Ⅲ St
 udy of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab 
 Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer\nE
 stimated primary completion: 27 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06764875
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885384-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290428
DTEND;VALUE=DATE:20290429
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07885384)
DESCRIPTION:Capecitabine\, phase 3\, Colorectal Cancer.\nStudy: Fruquintini
 b Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resecti
 on and Perioperative Chemotherapy in Patients With Liver-Only Metastatic C
 olorectal Cancer\nEstimated primary completion: 28 April 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07885384
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07413939-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT07413939)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: RO7771950 Versus Tucatinib in
  Combination With Trastuzumab and Capecitabine in People With Locally Adva
 nced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Rec
 eptor 2 (HER2)-Positive\nEstimated primary completion: 1 May 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07413939
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06245889-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06245889)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: PET Dynamics to Response-Adapte
 d Neoadjuvant Therapy in TNBC\nEstimated primary completion: June 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06245889
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06291064-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06291064)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Trial Studying Chemotherapy in 
 Nigerian Women With Triple Negative Breast Cancer\nEstimated primary compl
 etion: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cap
 ecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06291064
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987123-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06987123)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: TC as Adjuvant Therapy After Su
 rgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-
 arm Clinical Trial\nEstimated primary completion: 1 June 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06987123
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05203172-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Capecitabine: Phase 4 readout est. (NCT05203172)
DESCRIPTION:Capecitabine\, phase 4.\nStudy: The FLOTILLA Study: Providing C
 ontinued Access to The Study Medicines Encorafenib and Binimetinib for Par
 ticipants in Prior Clinical Trials\nEstimated primary completion: 31 July 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT052031
 72
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829757-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Capecitabine: Phase 4 readout est. (NCT07829757)
DESCRIPTION:Capecitabine\, phase 4\, Gastric Cancer.\nStudy: A Study of Zol
 betuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With 
 Gastric Cancer\nEstimated primary completion: 31 July 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07829757
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881017-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06881017)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Establishment 
 of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based
  on Novel Molecular Subtyping\nEstimated primary completion: 1 August 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06881017
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631052-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07631052)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Capecitabine in ER+/HER2-negati
 ve Breast Cancer\nEstimated primary completion: 1 August 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07631052
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431281-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290816
DTEND;VALUE=DATE:20290817
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07431281)
DESCRIPTION:Capecitabine\, phase 3\, Gastric Cancer.\nStudy: Sonesitatug Ve
 dotin in Combination With Capecitabine With or Without Rilvegostomig in Pa
 rticipants With Advanced or Metastatic Gastric\, Gastroesophageal Junction
 \, or Esophageal Adenocarcinoma Expressing Claudin18.2\nEstimated primary 
 completion: 16 August 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07431281
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Capecitabine: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Pan Tumor Rollover Study\nEstim
 ated primary completion: 25 August 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07869628-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07869628)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Multicenter\, Randomized\, Co
 ntrolled Phase III Clinical Trial on Adjuvant Intensified Therapy for Pati
 ents With Residual Disease After Neoadjuvant Treatment for Triple-negative
  Breast Cancer\nEstimated primary completion: 31 August 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07869628
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06469944-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20290912
DTEND;VALUE=DATE:20290913
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06469944)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: Substudy 06C: A Study of Inve
 stigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Partic
 ipants With First-Line Locally Advanced Unresectable/Metastatic Gastroesop
 hageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)\nEstimated primary comple
 tion: 12 September 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06469944
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683949-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07683949)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: Clinical 
 Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients 
 With Advanced Colorectal Cancer Refractory to Irinotecan\, Oxaliplatin\, a
 nd Fluoropyrimidine\nEstimated primary completion: 31 October 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07683949
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06434493-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Capecitabine: Phase na readout est. (NCT06434493)
DESCRIPTION:Capecitabine\, phase na.\nStudy: Evaluation of Combined Modalit
 y Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma\nEstima
 ted primary completion: 1 November 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06434493
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222215-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07222215)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in
  ER+ Breast Cancer (CAPELA)\nEstimated primary completion: 1 December 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07222215
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07238569-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07238569)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Phase III Trial of EBV-DNA-Guid
 ed Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma\nEstimated
  primary completion: 1 December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07238569
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365592-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07365592)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: Neoadjuva
 nt Chemotherapy\, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced 
 pMMR CRC\nEstimated primary completion: 1 December 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07365592
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04166318-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT04166318)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Lower-Dose Chemoradiation in Tr
 eating Patients With Early-Stage Anal Cancer\, the DECREASE Study\nEstimat
 ed primary completion: 31 December 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04166318
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797635-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06797635)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Study of Patritumab Deruxtecan 
 Plus Pembrolizumab With Other Anticancer Agents in Participants With High-
 Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Ne
 gative Breast Cancer (MK-1022-010\, HERTHENA-Breast-03)\nEstimated primary
  completion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06797635
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283367-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07283367)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: A Phase I
 b/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer
  Patients.\nEstimated primary completion: 31 December 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07283367
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07383285-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07383285)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: CAPOX and Bevacizumab With or W
 ithout Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as Firs
 t-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer\nEstimated pr
 imary completion: 31 December 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07383285
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877597-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07877597)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Chemotherapy Combined With or W
 ithout Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant 
 Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS\nEstimat
 ed primary completion: 31 December 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07877597
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686796-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07686796)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Anti-PCSK9 Antibody Tafolecimab
  and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiothe
 rapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective\, Multic
 enter\, Randomized\, Open-Label\, Parallel-Controlled Trial\nEstimated pri
 mary completion: 1 January 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07686796
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06205485-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300130
DTEND;VALUE=DATE:20300131
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06205485)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Neoadjuvant Chemotherapy\, Exci
 sion And Observation vs Chemoradiotherapy For Rectal Cancer\nEstimated pri
 mary completion: 30 January 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06205485
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07801027-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Capecitabine: Phase 4 readout est. (NCT07801027)
DESCRIPTION:Capecitabine\, phase 4.\nStudy: A Trial of Pembrolizumab With C
 hemotherapy or Chemoradiotherapy in Participants From India With Different
  Types of Cancer (MK-3475-G44/KEYNOTE-G44)\nEstimated primary completion: 
 31 January 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cape
 citabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07801027
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06277050-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300220
DTEND;VALUE=DATE:20300221
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06277050)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Maintenance Therapy With Toripa
 limab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharynge
 al Carcinoma\nEstimated primary completion: 20 February 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06277050
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432295-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07432295)
DESCRIPTION:Capecitabine\, phase 2\, Gastric Cancer.\nStudy: Givastomig Com
 bined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Met
 astatic Gastric Cancer (GIVA-2)\nEstimated primary completion: March 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07432295
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392866-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT07392866)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: A Clinical Study of SH006 Inj
 ection in Combination Therapy Versus Regorafenib in the Treatment of Advan
 ced Hepatocellular Carcinoma\nEstimated primary completion: 1 March 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07392866
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928584-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300310
DTEND;VALUE=DATE:20300311
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06928584)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Hypofractionated Radiotherapy P
 lus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Re
 ctal Cancer\nEstimated primary completion: 10 March 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06928584
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06900218-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300501
DTEND;VALUE=DATE:20300502
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06900218)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: PD-1 Antibody Sintilimab Combin
 ed With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carc
 inoma\nEstimated primary completion: 1 May 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06900218
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854964-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300515
DTEND;VALUE=DATE:20300516
SUMMARY:Capecitabine: Phase na readout est. (NCT07854964)
DESCRIPTION:Capecitabine\, phase na.\nStudy: A Prospective\, Single-center\
 , Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in 
 Locally Advanced Rectal Cancer\nEstimated primary completion: 15 May 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07854964
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07021261-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300616
DTEND;VALUE=DATE:20300617
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07021261)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Comparing UTD2 Combined With Ca
 pecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients\n
 Estimated primary completion: 16 June 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07021261
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309419-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT07309419)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: A Phase III Randomized Study 
 of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Tar
 geted Immunotherapy in Unresectable Hepatocellular Carcinoma\nEstimated pr
 imary completion: 30 June 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07309419
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281768-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07281768)
DESCRIPTION:Capecitabine\, phase 2\, Colorectal Cancer.\nStudy: Capecitabin
 e/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REG
 N7075 in Locally Advanced Rectal Cancer\nEstimated primary completion: Jul
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0728
 1768
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05610163-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT05610163)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: Testing the Addition of an An
 ti-Cancer Drug\, Irinotecan\, to the Standard Chemotherapy Treatment (FOLF
 OX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers 
 to Improve the Rate of Complete Response and Long-Term Rates of Organ Pres
 ervation and Continuing Response\nEstimated primary completion: 1 July 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05610163
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02491697-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Capecitabine: Phase 2 readout est. (NCT02491697)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Immunotherapy Combined With Capecitabine Versus Capecitabine Monothe
 rapy in Advanced Breast Cancer\nEstimated primary completion: August 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT02491697
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805551-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07805551)
DESCRIPTION:Capecitabine\, phase 1/2\, Colorectal Cancer.\nStudy: A Study o
 f HDM2017 Combination Therapy in Advanced Colorectal Cancer\nEstimated pri
 mary completion: August 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07805551
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841679-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT06841679)
DESCRIPTION:Capecitabine\, phase 2/3.\nStudy: Utidelone Capsule Combined Wi
 th Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatme
 nt of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma\nE
 stimated primary completion: 1 September 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06841679
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791758-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20300904
DTEND;VALUE=DATE:20300905
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT07791758)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: A Clinical Trial of LBL-024 C
 ombination Drug in Patients With Metastatic Colorectal Carcinoma\nEstimate
 d primary completion: 4 September 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07791758
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06525766-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20301015
DTEND;VALUE=DATE:20301016
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06525766)
DESCRIPTION:Capecitabine\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Po
 sitive\, HER2 Negative Breast Cancer\nEstimated primary completion: 15 Oct
 ober 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6525766
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958328-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20301021
DTEND;VALUE=DATE:20301022
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06958328)
DESCRIPTION:Capecitabine\, phase 3\, Pancreatic Cancer.\nStudy: Testing Hig
 her Dose Radiation Therapy for Locally Advanced Pancreatic Cancer\nEstimat
 ed primary completion: 21 October 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06958328
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07580339-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07580339)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Combining DCSZ11 With Radiation
  and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Recta
 l Cancer\nEstimated primary completion: November 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07580339
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07590024-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07590024)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: RAIRI Model-Guided Adjuvant The
 rapy in Nasopharyngeal Carcinoma\nEstimated primary completion: 31 Decembe
 r 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0759
 0024
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904819-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07904819)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Risk-Adapted Anlotinib and PD-L
 1 for Locoregionally Advanced Nasopharyngeal Carcinoma\nEstimated primary 
 completion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07904819
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392320-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20310210
DTEND;VALUE=DATE:20310211
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07392320)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A Phase II Trial Comparing Immu
 notherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy fo
 r High-risk Nasopharyngeal Carcinoma\nEstimated primary completion: 10 Feb
 ruary 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitab
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07392320
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340541-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20310602
DTEND;VALUE=DATE:20310603
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07340541)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Evolutionary Clinical Trial for
  Novel Biomarker-Driven Therapies\nEstimated primary completion: 2 June 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07340541
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06134375-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20310626
DTEND;VALUE=DATE:20310627
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06134375)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: A Study of Tetrathiomolybdate
  (TM) Plus Capecitabine\nEstimated primary completion: 26 June 2031. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06134375
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04383275-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20310706
DTEND;VALUE=DATE:20310707
SUMMARY:Capecitabine: Phase 2 readout est. (NCT04383275)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Stage I HER2 Positive Invasive 
 Breast Cancer De-escalation Study(IRIS)\nEstimated primary completion: 6 J
 uly 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 383275
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05934331-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20310806
DTEND;VALUE=DATE:20310807
SUMMARY:Capecitabine: Phase 2 readout est. (NCT05934331)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A LM-302 Combination With Other
  Anti-Tumor Therapies Phase ll Study\nEstimated primary completion: 6 Augu
 st 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059
 34331
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06313463-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06313463)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Study Of Capecitabine Combined 
 With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy\
 nEstimated primary completion: September 2031. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06313463
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154069-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07154069)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Adaptive Immunotherapy for Naso
 pharyngeal Carcinoma\nEstimated primary completion: September 2031. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07154069
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04929028-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20310915
DTEND;VALUE=DATE:20310916
SUMMARY:Capecitabine: Phase 2 readout est. (NCT04929028)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Therapy Adapted for High Risk a
 nd Low Risk HIV-Associated Anal Cancer\nEstimated primary completion: 15 S
 eptember 2031. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capeci
 tabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04929028
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910760-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20311011
DTEND;VALUE=DATE:20311012
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07910760)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: TRINITY TRIAL\; Trial Of PRRT P
 lus CAPTEM Vs CAPTEM Alone In Well Differentiated GEP NETS\nEstimated prim
 ary completion: 11 October 2031. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07910760
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829783-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20311117
DTEND;VALUE=DATE:20311118
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07829783)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Clinical Trial of Sacituzumab
  Tirumotecan (Sac-TMT\, MK-2870) and Pembrolizumab (MK-3475A) in Participa
 nts With Bladder Cancer (MK-2870-055)\nEstimated primary completion: 17 No
 vember 2031. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecita
 bine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07829783
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07524413-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07524413)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Dynamic Plasma EBV DNA-Guided R
 isk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade i
 n Locoregionally Advanced Nasopharyngeal Carcinoma\nEstimated primary comp
 letion: December 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07524413
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07248670-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07248670)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Concurrent Chemoradiotherapy Wi
 th or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC\nEstimated
  primary completion: 31 December 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07248670
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467330-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07467330)
DESCRIPTION:Capecitabine\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitab
 ine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatmen
 t\nEstimated primary completion: 31 December 2031. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07467330
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07521605-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07521605)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Short-Course Radiotherapy\, Nal
 -IRI\, Capecitabine\, and Camrelizumab for Locally Advanced MSS Rectal Can
 cer\nEstimated primary completion: 31 December 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07521605
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554521-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07554521)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: A Study to Evaluate Efficacy an
 d Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectab
 le or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal
  Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the Uni
 ted States\nEstimated primary completion: 31 December 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07554521
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766772-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT07766772)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: Trastuzumab Rezetecan Followed 
 by Pyrotinib\, and Trastuzumab Combined With Capecitabine as First-line Tr
 eatment for Advanced HER2-positive Breast Cancer\nEstimated primary comple
 tion: 31 December 2031. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07766772
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06374459-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT06374459)
DESCRIPTION:Capecitabine\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Zunsemetinib in Combination With Capecitabine in Patients With Hor
 mone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bon
 e Metastasis\nEstimated primary completion: 31 May 2032. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06374459
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07332533-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Capecitabine: Phase 2/3 readout est. (NCT07332533)
DESCRIPTION:Capecitabine\, phase 2/3\, Gastric Cancer.\nStudy: A Study of K
 N026-based Combination Therapy in HER2-positive Gastric Cancer\nEstimated 
 primary completion: 30 June 2032. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/capecitabine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07332533
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340567-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20321101
DTEND;VALUE=DATE:20321102
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07340567)
DESCRIPTION:Capecitabine\, phase 3\, Colorectal Cancer.\nStudy: Personalizi
 ng Chemotherapy Selection After Surgery for Patients With Stage III Colore
 ctal Cancer Using a Blood Test\nEstimated primary completion: 1 November 2
 032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0734056
 7
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551479-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07551479)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: SCRT Based iTNT vs. LCRT Based 
 TNT for MSS Locally Advanced Rectal Cancer\nEstimated primary completion: 
 31 December 2032. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cap
 ecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07551479
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966700-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20330323
DTEND;VALUE=DATE:20330324
SUMMARY:Capecitabine: Phase 3 readout est. (NCT06966700)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: A Clinical Study of Sacituzumab
  Tirumotecan (Sac-TMT\, MK-2870) in People With Breast Cancer (MK-2870-032
 )\nEstimated primary completion: 23 March 2033. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/capecitabine#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06966700
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05314998-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20330401
DTEND;VALUE=DATE:20330402
SUMMARY:Capecitabine: Phase 3 readout est. (NCT05314998)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Adjuvant Trial in Patients With
  Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-bas
 ed Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treat
 ment Specific Stratification Signature\nEstimated primary completion: 1 Ap
 ril 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 314998
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745296-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20330702
DTEND;VALUE=DATE:20330703
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07745296)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Investigating Precision Medicin
 e in the Adjuvant Setting in Biliary Tract Cancer\nEstimated primary compl
 etion: 2 July 2033. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 apecitabine#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07745296
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06085742-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20340930
DTEND;VALUE=DATE:20341001
SUMMARY:Capecitabine: Phase 2 readout est. (NCT06085742)
DESCRIPTION:Capecitabine\, phase 2.\nStudy: BRE-08 Phase II Study of CMC Re
 gimen for Early Stage Breast Cancer\nEstimated primary completion: Septemb
 er 2034. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/capecitabine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT060
 85742
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591493-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20350630
DTEND;VALUE=DATE:20350701
SUMMARY:Capecitabine: Phase 3 readout est. (NCT07591493)
DESCRIPTION:Capecitabine\, phase 3.\nStudy: Adjuvant Trial in Pancreatic Ne
 uroendocrine Tumors\nEstimated primary completion: June 2035. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07591493
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02598349-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20391031
DTEND;VALUE=DATE:20391101
SUMMARY:Capecitabine: Phase 2 readout est. (NCT02598349)
DESCRIPTION:Capecitabine\, phase 2\, Pancreatic Cancer.\nStudy: Proton Radi
 ation for Unresectable\, Borderline Resectable\, or Medically Inoperable C
 arcinoma of the Pancreas\nEstimated primary completion: October 2039. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/capecitabine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT02598349
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05849480-9047@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20400601
DTEND;VALUE=DATE:20400602
SUMMARY:Capecitabine: Phase 1/2 readout est. (NCT05849480)
DESCRIPTION:Capecitabine\, phase 1/2.\nStudy: A Study of CDX-1140\, a CD40 
 Agonist\, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Key
 truda in Subjects With Biliary Tract Carcinoma (BTC)\nEstimated primary co
 mpletion: 1 June 2040. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/capecitabine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05849480
URL:https://assetmemo.bio/drug/capecitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
